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Abstract
Objective To quantify and compare the treatment effect and risk of bias
of trials reporting biomarkers or intermediate outcomes (surrogate
outcomes) versus trials using final patient relevant primary outcomes.
Design Meta-epidemiological study.
Data sources All randomised clinical trials published in 2005 and 2006
in six high impact medical journals: Annals of Internal Medicine, BMJ,
Journal of the American Medical Association, Lancet, New England
Journal of Medicine, and PLoS Medicine.
Study selection Two independent reviewers selected trials.
Data extraction Trial characteristics, risk of bias, and outcomes were
recorded according to a predefined form. Two reviewers independently
checked data extraction. The ratio of odds ratios was used to quantify
the degree of difference in treatment effects between the trials using
surrogate outcomes and those using patient relevant outcomes, also
adjusted for trial characteristics. A ratio of odds ratios >1.0 implies that
trials with surrogate outcomes report larger intervention effects than
trials with patient relevant outcomes.
Results 84 trials using surrogate outcomes and 101 using patient
relevant outcomes were considered for analyses. Study characteristics
of trials using surrogate outcomes and those using patient relevant
outcomes were well balanced, except for median sample size (371 v
741) and single centre status (23% v 9%). Their risk of bias did not differ.
Primary analysis showed trials reporting surrogate endpoints to have
larger treatment effects (odds ratio 0.51, 95% confidence interval 0.42
to 0.60) than trials reporting patient relevant outcomes (0.76, 0.70 to
0.82), with an unadjusted ratio of odds ratios of 1.47 (1.07 to 2.01) and
adjusted ratio of odds ratios of 1.46 (1.05 to 2.04). This result was
consistent across sensitivity and secondary analyses.
Conclusions Trials reporting surrogate primary outcomes are more
likely to report larger treatment effects than trials reporting final patient
relevant primary outcomes. This finding was not explained by differences
in the risk of bias or characteristics of the two groups of trials.
Introduction
Evidence for the effectiveness of treatments should ideally come
from randomised clinical trials or systematic reviews of trials
that assess final endpoints relevant to patients, such as survival
or health related quality of life.1 2However, aspects of the design
and conduct of randomised clinical trials have been shown to
lead to overestimation of treatment effect size. These include
inappropriate random sequence generation,3 inadequate
allocation concealment,4 5 lack of blinding,6 single centre
status,7 8 and the use of composite outcomes.9
Surrogate outcomes are often used in clinical trials as substitutes
for final patient relevant outcomes. Advantages of surrogate
outcomes over final outcomes are that they may occur faster or
may be easier to assess, thereby shortening the duration, size,
and cost of trials.10 11 A key rationale for the use of surrogate
outcomes in trials is not only substitution12 but the prediction
of treatment benefit in the absence of data on patient relevant
outcomes.13-15 Several drugs have been licensed on this
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basis—for example, statins (based on low density lipoprotein
levels), AIDS drugs (based on HIV RNA or CD4 count levels),
and cancer drugs (based on time to progression or disease-free
survival).16
Despite the potential appeal of using surrogate outcomes, the
use of such trials in policy making remains controversial.11 17 18
Gefitinib, an orally administered epidermal growth factor
receptor tyrosine kinase inhibitor, was approved by the Food
and Drugs Administration in the United States for marketing in
May 2003 for patients with non-small cell lung cancer based
on the surrogate outcome of tumour response rate. The initial
approved indication was for the treatment of patients who were
refractory to established cancer treatments (both a platinum
drug and docetaxel).19 In 2005, however, data from two clinical
studies became available showing no significant survival benefit;
the FDA released a new labelling for gefitinib that prevented
its use in new patients with non-small cell lung cancer, limiting
its usage to only continuation in those patients with cancer who
had already taken the medicine and whose doctor believed it
was helping them.20 Although often cited by sceptics, this and
other such potentially complete failures of surrogate
outcomes21-23 remain relatively rare.
Given the growing pressure for faster access to innovative
treatments for patients, reimbursement decisions for new
treatments are now oftenmade at or around the time of licensing,
increasing pressure to rely on treatment effects from trials
reporting surrogate primary outcomes.24 25 Such reimbursement
decisions often depend on the use of economic modelling to
extrapolate treatment effects based on surrogate outcomes into
an estimate of cost effectiveness, such as the incremental cost
per quality adjusted life year (QALY), the metric currently
recommended by the National Institute for Health and Clinical
Excellence.13 26
We quantified and compared the treatment effects in a sample
of randomised clinical trials reporting either a surrogate or final
patient relevant primary outcome. We also compared the risk
of bias in these two groups of trials.
Methods
We searched Medline through PubMed for randomised clinical
trials published in 2005 and 2006 in six high impact (impact
factor >14 in 2011 according to ISIWeb of Knowledge) medical
journals—that is, Annals of Internal Medicine, BMJ, Journal
of the American Medical Association, New England Journal of
Medicine, Lancet, and PLoSMedicine (see supplementary table
1 for details of search strategy). We purposively chose general
(rather than specialist) medical journals as we sought to compare
surrogate and final patient relevant outcomes across a broad
range of medical conditions. Otherwise our two year sampling
frame was based on a recent study that examined the reporting
of surrogate outcomes in trials.27 The study authors provided us
with their listing of trials and we checked that this captured all
randomised clinical trials from our database search.
Study selection
Two authors (OC, RST) independently undertook the inclusion
and exclusion of trials (see box).
We classified studies into two groups according to whether the
primary outcome was a surrogate one or a final patient relevant
one. A final patient relevant outcome was defined as any
outcome that captures “how a patient feels, functions or
survives.”30 An outcome was consequently classified as a
surrogate if it was a biomarker12 (for example, low density
lipoprotein cholesterol level) or an intermediate outcome (for
example, progression-free survival)13 31 judged to be a substitute
for a final outcome.Where a trial did not state outcome primacy,
we chose the one used for sample size calculation or the first
outcome reported in the results section to be the primary
outcome. As some subjectivity is involved in classification of
outcomes as surrogate or final, two reviewers (OC, RST)
resolved borderline cases by review of the full paper and
discussion. To obtain comparable groups of trials using surrogate
and final patient relevant outcomes, we used a hierarchical
matching process to match each included surrogate outcome
trial with a corresponding final patient relevant outcome trial,
based on four criteria: the intervention clinical area, clinical
population, journal, and publication year (see supplementary
file for details of matched studies). After further detailed review
of full papers, additional exclusions were necessary to omit
trials with mixed primary outcome assessment and trials that
were terminated early. As we sought to examine differences in
treatment effects between trials using surrogate outcomes and
those using final patient relevant outcomes, we excluded
equivalence and non-inferiority designs.
Data extraction and risk of bias assessment
Using a predefined data extraction form we extracted data from
the included trials on journal, sample size, patient population,
type of intervention (drug, medical device, surgical procedure,
health promotion activity, other therapeutic intervention32),
duration of follow-up, centre status (single or multicentre), and
sponsor (for profit, not for profit, or mixed33). For trials using
surrogate outcomes we sought additional information on type
of surrogate (imaging, histochemical/biochemical, instrumental,
other), whether the authors explicitly reported that they had
used a surrogate outcome (for example, the outcome was
labelled as a “surrogate outcome,” “intermediate outcome”, or
“non-clinical outcome”, or it was clearly understood in the
context of the article that the outcome was a surrogate), and
what authors reported in the publication on validity of the
surrogate outcome.13 34 We assessed risk of bias in terms of the
adequacy of random sequence generation and concealment,
statement of double blind placebo controlled trial, and use of
intention to treat analyses. One reviewer (OC) initially undertook
data extraction and risk of bias assessment, and this was then
checked by a second reviewer (TP or RST).
Data analyses
We compared the treatment effects between the two trial types
using several analytical approaches. In accord with previous
studies, for our primary analysis we sought binary outcomes in
each trial recorded as the number of patients and events in each
arm.3-7 35Outcome events were recoded where necessary so that
an odds ratio below 1.0 indicated beneficial effect of the
intervention. Metaregression is a technique used to explore the
relation between study characteristics (for example, sample size
and journal of publication) and effect size.36 We used random
effects logistic metaregression models35 to estimate ratios of
odds ratios and 95% confidence intervals comparing treatment
effects in trials using surrogate outcomes and final patient
relevant outcomes. Ratio of odds ratios greater than 1.0 implied
greater (more beneficial) treatment effects in the trials using
surrogate outcomes than in the trials using final patient relevant
outcomes. To take account of potential confounding, in our
primary analysis we also included an adjusted analysis that
incorporated predefined trial level covariates in the
metaregression model—that is, clinical area of the treatment
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Inclusion criteria
• Randomised clinical trial
• Publication years 2005-06
• Journals (Annals of Internal Medicine, BMJ, Journal of the American Medical Association, New England Journal of Medicine, Lancet,
PLoS Medicine)
• Interventional studies
Exclusion criteria
• Non-interventional studies (e.g. evaluations of screening or diagnostic tests)
• Economic evaluations
• Mixed primary outcomes (i.e. a primary outcome that comprised both a surrogate and final patient relevant outcome*)
• Multi-arm trials
• Secondary analyses
• Early terminated studies
• Equivalence or non-inferiority design
• No analysable data
*Two examples of mixed primary outcomes seen in this study were a composite endpoint of death or vein graft restenosis28
and a composite of serum creatinine level, end stage renal disease, or death29
and patient population, intervention type, sponsor, journal,
sample size, and mean follow-up time.
To assess the robustness of the primary analysis, we undertook
several sensitivity analyses. Firstly, to maximise the number of
studies in our analysis we first included trials that failed to report
the number of patients and events in each arm but reported their
results as a risk ratio (that is, relative risk, odds ratio, or hazard
ratio). A pooled relative risk ratio comparing trials using
surrogate outcomes with those using final patient relevant
outcomes was estimated with inclusion of these trials. Secondly,
for studies reporting continuous outcomes we first calculated a
Cohen’s standardised mean difference and associated standard
errors. We then transformed the standardised mean differences
to log odds ratios and combined them with studies reporting
binary outcome or risk ratios using random effects
meta-analysis.36 37 Thirdly, we estimated log odds ratios and
associated standard errors for each matched pair of trials, using
the method of Bucher et al,38 and combined across trials using
random effects meta-analysis. Sensitivity analyses are reported
as unadjusted ratio of odds ratios (or relative risk ratios) and
adjusted for trial covariates.
In a secondary analysis, we classified the trials using surrogate
outcomes and final patient relevant outcomes according to
whether the reported result for the primary outcomewas positive
(the treatment group was superior to control, P≤0.05), negative
(the control group was superior to treatment, P≤0.05), or neutral
(no significant difference between groups, P>0.05). We then
compared the outcomes using an unadjusted logistic regression
model and a model adjusted for study level covariates.
For both primary and secondary analyses, when not explicitly
stated, we considered the latest available follow-up. Trials with
multi-arms were included if it was possible and clinically
meaningful to pool the number of events across arms towards
a unique comparator—for example, different dosages of the
same drug versus placebo arm.When treatment effect estimates
and their variability were only shown graphically we used the
open source software WinDig version 2.5 to extract numbers
from the graphically presented information.
A regression test for funnel plot asymmetry was performed to
assess small study effects and potential publication bias.39 All
analyses were run in Stata SE version 12.
Results
A total of 639 titles and abstracts were identified, 511 of which
were identified as eligible for the study. Of these, 27% (n=137)
were judged to use a surrogate primary outcome. After matching
and exclusions, 185 trials contributed to the quantitative analyses
(fig 1⇓). See the supplementary file for a list of included trials.
The fidelity of matching of trials using surrogate outcomes and
those using final patient relevant outcomes seemed to be retained
in these 185 trials (table 1⇓) and in the subgroup of trials
reporting binary primary outcomes (data not shown). In both
groups, drug interventions (surrogate: 58%; final: 61%, P=0.33)
and not for profit sponsorship (surrogate: 58%; final: 56%,
P=0.86) were most common. Trials using final patient relevant
outcomes had a larger median sample size than trials using
surrogate outcomes (P<0.001) and were also more likely to be
multicentre (P=0.01). Follow-up between the two groups of
trials did not differ significantly (P=0.73). Although the duration
of the trials was similar overall, when chronic conditions, such
as cardiovascular disease, cancer, and endocrine disorders, were
considered, the trials using surrogate outcomes had a shorter
median follow-up (255 v 730 days, P=0.03).
Trials with surrogate outcomes used laboratory biomarkers
(52/137, 38%) such as prostate specific antigen; imaging
(35/137, 25.5%) such as left ventricular ejection fraction; or
instrumental endpoints (35/137, 25.5%) such as body weight.
Fifteen trials were judged to use an intermediate outcome to
substitute for a final outcome (15/137, 11%), such as
disease-free survival or rate of ovulation. In fewer than half of
the cases (36/84, 43%) authors explicitly stated they used a
surrogate outcome and provided criteria or references for its
validation in 28 out of 84 trials (35%).
Comparison of treatment effects
Primary analysis
Overall, 134 trials (51 surrogate outcome trials and 83 final
outcome trials) reporting binary outcomes in the primary
analysis were included. The pooled odds ratio for the primary
outcome in the surrogate trials was 0.51 (95% confidence
interval 0.42 to 0.60; I2=91.2%, P<0.001) compared with 0.76
(0.70 to 0.82; I2=89.8%, P<0.001) in trials using final patient
relevant outcome. On average the treatment effect estimate was
47% higher in the trials using surrogate outcomes than in the
trials using final patient relevant outcomes (ratio of odds ratios
1.47, 95% confidence interval 1.07 to 2.01, P=0.02). This
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difference remained after adjustment for characteristics of the
trials (1.46, 1.05 to 2.04, P=0.03, table 2⇓).
Sensitivity analyses
After incorporating trials with risk ratios as reported by the
authors, 143 trials (57 surrogate outcome trials and 86 final
outcome trials) were included. The treatment estimates in the
trials using surrogate outcomes remained higher than in the ones
using final patient relevant outcomes (unadjusted relative risk
ratios 1.38, 95% confidence interval 1.12 to 1.71, P<0.01;
adjusted relative risk ratios 1.36, 1.08 to 1.70, P<0.01). After
combining continuous and binary outcomes in the overall
sample, the estimated ratio of odds ratios showed a similar
direction of effect (unadjusted 1.44, 95% confidence interval
0.83 to 2.49, P=0.20; adjusted 1.48, 0.83 to 2.62, P=0.18). A
total of 43 pairs of matched trials were available for a paired
analysis, with a pooled ratio of odds ratios of 1.38 (1.01 to 1.88,
P=0.04).
Secondary analysis
Trials using surrogate outcomes were more likely to obtain a
positive result (as stated by the authors) in favour of the
treatment (52/84, 62%) than trials using final patient relevant
outcomes (37/101, 37%). The odds ratio of reporting a positive
result in the trials using surrogate outcomes compared with trials
using final patient relevant outcomes was 2.17 (95% confidence
interval 1.20 to 3.92, P=0.01) and 2.43 (1.29 to 4.57, P<0.01)
after adjustment for the characteristics of the trials.
Influence of trial characteristics
No trial characteristics showed a statistically significant
association with treatment effect estimates in bivariate
metaregression models, in addition to type of primary endpoint,
except for sample size and single centre status. Harbord’s
modified test showed similar levels of small study bias in both
the trials using surrogate outcomes (t=3.63; P=0.001) and the
trials using final patient relevant outcomes (t=2.79; P=0.007;
see the funnel plot in the supplementary file). We undertook a
retrospective analysis including centre status as trial level
covariate in the primary analysis adjusted model, resulting in a
ratio of odds ratios of 1.28 (95% confidence interval 0.96 to
1.72, P=0.09). There was no evidence of an interaction between
the primary analysis ratio of odds ratios of trials using surrogate
outcomes compared with trials using final patient relevant
outcomes and the characteristics of the trials (fig 2⇓).
Risk of bias
The risk of bias between trials using surrogate outcomes and
those using final patient relevant outcomes did not differ
significantly (table 3⇓). Further adjustment of themetaregression
estimates for these four factors did not change the inference of
the primary analysis comparing trials using surrogate and final
patient relevant outcomes—that is, risk of bias adjusted ratio
of odds ratios 1.45 (95% confidence interval 1.06 to 1.99,
P=0.02). No risk of bias characteristic was found to be
significantly associated with treatment effect and there was no
interaction with the primary analysis ratio of odds ratios of trials
using surrogate outcomes compared with those using final
patient relevant outcomes (fig 2).
Discussion
We provide empirical evidence that trials using surrogate
primary outcomes report larger treatment effects than a matched
sample of trials using final patient relevant primary outcomes.
We analysed a cohort of randomised clinical trials categorised
according to whether their primary outcome was surrogate or
a final patient relevant endpoint and matched on the basis of
key characteristics of the trials. On average, trials using
surrogate outcomes reported treatment effects that were 28%
to 48% higher than those of trials using final patient relevant
outcomes. Furthermore, we found that surrogate trials were
twice as likely to report positive treatment effects as the final
outcome trials. These findings were not explained by differences
in risk of bias or other trial characteristics and are comparable
with the level of exaggeration of treatment effect attributed to
inadequate allocation concealment.5 Although, as anticipated,
we found that trials with a patient relevant primary outcome
were more likely to have larger sample sizes, two groups of
trials had similar average follow-up times. However, when
limited to trials of chronic conditions, follow-up was longer for
trials using final patient relevant outcomes. Given the range of
interventions and outcomes included, substantial statistical
heterogeneity was evident in treatment effects in both types of
trials.
Comparison of our findings with previous
studies
Few studies have empirically compared trials reporting surrogate
and final primary outcomes. One study33 reviewed 324
consecutive cardiovascular trials published in major general
medical journals between 2000 and 2005. In accord with the
findings of the present study, trials reporting surrogate primary
outcomes were more likely to report a positive treatment effect
(77 out of 115 trials, 67%) than trials reporting final patient
related primary outcomes (113 out of 209 trials, 54%, P=0.02).
A recent systematic review of anti-tumour necrosis factor agents
for rheumatoid arthritis40 compared the methodological quality
of trials reporting surrogate primary outcomes with those with
final primary outcomes. In contrast with the present study, a
difference in study quality between the two groups of trials was
seen; the mean percentage of items met in the consolidated
standards of reporting trials (CONSORT) statement was lower
for studies with surrogate outcomes than with final patient
relevant outcomes (62.5 v 70.7, P=0.03). However, as this
systematic review included both randomised and
non-randomised trials, and fewer studies with surrogate
outcomes were randomised (63% v 74%), this finding is likely
to be confounded.
Several reasons may explain why trials assessing surrogate
endpoints showed larger treatment effects than trials assessing
final endpoints. The first relate to small study effects—the
tendency for smaller studies to show a large treatment effect.41
As expected, we found a smaller sample size for trials using
surrogate outcomes than for trials using final patient relevant
outcomes. However, our results remained consistent after
adjustment for the sample size of the trials. A second reason
may relate to publication bias. Althoughwe observed substantive
small study bias and therefore potential publication bias, the
extent of this bias seemed similar across the two sets of trials.
Furthermore, it may be argued that published results based on
surrogate outcomes are more likely to be positive as the
requirements for publication of such results are generally more
stringent, whereas results based on (definitive) final endpoints
are more likely to be published regardless of the trial’s findings.
Thirdly, trials using surrogate outcomes may be of lower
methodological quality than trials using final patient relevant
outcomes and therefore more prone to exaggeration of effect
size.40 However, a comparison of risk of bias between the two
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groups of randomised clinical trials showed no differences in
random sequence generation, allocation concealment, blinding,
and intention to treat analysis. Furthermore, our results were
consistent after adjustment for these risks of bias dimensions.
Fourthly, two recent meta-epidemiological studies have shown
that single centre trials are more likely than multicentre trials
to lead to larger intervention effects.7 8 In our sample a higher
proportion of the trials using surrogate outcomes were single
centre trials compared with the trials using final patient relevant
outcomes. However, an additional retrospective sensitivity
analysis including adjustment for centre status showed consistent
results, with use of surrogate outcomes still associated with
larger treatment effects.
Finally, the treatment effect may be truly larger in trials with
surrogate outcomes than with final patient relevant outcomes.
In the continuum of health outcomes measures, biomarkers and
intermediate outcomes can be identified as disease centered
measures, reflecting the biology of the disease process and the
underlying mechanism of disease.42 Assuming the surrogate
outcomes lie in the causal pathway between the onset of the
disease and the final patient relevant outcome, they are generally
more proximal (closer) to the disease and therefore more
sensitive to the effect of interventions with therapeutic purposes.
Limitations of the study
As our sample of randomised clinical trials was drawn from six
high impact general medical journals over two specific
consecutive calendar years, the findings may lack
generalisability.We purposively chose general medical journals
so as to compare surrogate and final patient related outcomes
across a range of medical conditions. Although the choice of
publication year would not be expected to influence treatment
effects, trials published in high impact journals, although
contributing a relatively small proportion of all published trials,43
are more likely to report newsworthy results.44 However, it is
unclear how this would have influenced the generalisability of
our findings. High impact journals might be expected to publish
trials of lower risk of bias. We observed higher methodological
quality of trials in our sample compared with a representative
sample of trials indexed in PubMed,44 therefore it could be
argued our findings are less likely to be susceptible to
confounding by other aspects of trial methodological quality.
In addition, we compared the treatment effects of a matched
sample of randomised clinical trials reporting surrogate primary
outcomes and final primary outcomes. Alternatively, we could
have compared the treatment effects between surrogate and final
outcomes within the same trials or meta-analyses of
homogeneous trials (a meta-epidemiological analysis).45
Although such a “within trial” comparison would minimise
confounding by study population, intervention type, and risk of
bias, this approach has problems. Firstly, trials are generally
powered to detect statistically significant differences in their
primary endpoint. Trials with surrogate primary outcomes may
be underpowered for final patient relevant outcomes and thus
lead to imprecision in the estimation of the comparative
treatment effect of surrogate and final outcomes. Secondly,
where within trial meta-analysis comparisons of surrogate and
final outcomes have been performed, they have been limited to
a single treatment (or treatment class) in one specific disease
area.46-49 In this study we sought to address a different
question—that is, in the absence of final patient relevant
outcomes, what is the potential effect of relying on the treatment
effects based on surrogate outcomes across a range of medical
conditions and interventions and surrogate outcome types? To
maximise their comparability we matched the cohorts of
surrogate and final trials on the basis of key study characteristics,
such as disease and intervention area.
Finally, the classification of primary outcomes as surrogate or
final patient relevant involves an element of subjective
judgment. For example, change in bodymass index50 and carbon
monoxide confirmed smoking abstinence rate51 were both
classified as surrogate outcomes, having assumed the patient
relevant outcomes in these cases to be long term decline in lung
function and lung cancer, respectively. To minimise assessment
bias, two reviewers independently applied a standard outcome
definition of surrogate and final patient relevant outcomes across
all trials, with discussion and consensus on any initial
disagreements. To our knowledge this is the first empirical study
designed to deal with this subject and therefore our results
should be verified in another sample.
Implications of the study
The potential for surrogate outcomes to impact on healthcare
policy making and the consequent diffusion of treatments into
practice is shown by the fact that 27% of the randomised clinical
trials identified during the two year study period reported
surrogate primary outcomes. In health technology assessment
reports, both in the United Kingdom13 and internationally,52
some 1 in 20 base their clinical and economic conclusions on
evidence from surrogate outcomes alone. That trial based
surrogate outcomes can lead to substantive overestimation of
treatment effects that would have been seen if evidence on
patient relevant outcomes was available is a salutary message
for policy makers when weighing up the evidence from use of
surrogate outcomes in their licensing and coverage decisions.
Several recent drug appraisals by the National Institute for
Health and Clinical Excellence have relied on evidence of
clinical effect derived solely from surrogate outcomes.53-55 Our
findings reinforce the importance of formally evaluating the
acceptability of biomarkers and intermediate outcomes as valid
surrogate outcomes and quantifying the association of treatment
effect between the surrogate and patient relevant final outcomes
and its uncertainty. The statistical validation of surrogates and
the quantification of the relation between surrogate and final
patient relevant outcomes are key problems tackled in NICE’s
update of its methodological guidance for technology
assessment.56 The updated version of methods guidance makes
several requirements for health technology assessment producers
when faced with clinical trials with evidence based on surrogate
outcomes (that is, a systematic review of the evidence to support
the validity of the surrogate outcome, clear statement of how
the relation between surrogate and final outcome is modelled
in determining cost effectiveness) and exploration of the
additional uncertainty associated with this prediction on cost
effectiveness estimates.26
Clinical trialists and systematic reviewers need to be clearer in
their reporting as to whether outcomes are surrogate or final
patient relevant, and appropriately frame any conclusions of
superiority of interventions when based on surrogate outcomes
alone. Others have recently suggested that guidance on
surrogates should be incorporated into the CONSORT
statement.27 Novel and adaptive approaches to trial design are
needed that allow surrogate endpoints to continue to be used as
primary outcomes, while also providing evidence on their
validation against patient relevant outcomes.57
Conclusions
In the absence of data on final outcome, policy makers need to
interpret intervention effects based on surrogate outcomes with
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caution. Although our results have highlighted the risks, they
support the application of methods for the validation and
quantification of the relations between surrogate and final patient
relevant outcomes in licensing and reimbursement decisions on
new and existing treatments.
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What is already known on this topic
Surrogate outcomes are used to substitute and predict for a final patient relevant outcome in clinical trials
Failures of specific surrogate outcomes have been reported in the literature
Licensing and coverage decisions of health technologies often rely on evidence based on surrogate outcomes
What this study adds
Trials reporting surrogate primary outcomes are more likely to report larger treatment effects than trials reporting final patient relevant
primary outcomes
In the absence of patient relevant outcomes, policy makers should rely on validated surrogate outcomes and take into account the
potential uncertainty in their prediction of treatment benefit and harm
56 National Institute for Health and Clinical Excellence. Review of the guide to the methods
of technology appraisal. 2012. www.nice.org.uk/aboutnice/howwework/devnicetech/
TAMethodsGuideReview.jsp?domedia=1&mid=CB13DD0D-19B9-E0B5-
D4AB0011AEE2B0E7.
57 Renfro LA, Carlin BP, Sargent DJ. Bayesian adaptive trial design for a newly validated
surrogate endpoint. Biometrics 2012;68:258-67.
Accepted: 29 October 2012
Cite this as: BMJ 2013;346:f457
This is an open-access article distributed under the terms of the Creative Commons
Attribution Non-commercial License, which permits use, distribution, and reproduction in
any medium, provided the original work is properly cited, the use is non commercial and
is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-
nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;346:f457 doi: 10.1136/bmj.f457 (Published 29 January 2013) Page 7 of 12
RESEARCH
 o
n
 6 July 2020 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.f457 on 29 January 2013. Downloaded from 
Tables
Table 1| Characteristics of trials using surrogate primary outcomes and final patient relevant primary outcomes. Values are numbers
(percentages) unless stated otherwise
Patient relevant outcomes (n=101)Surrogate outcomes (n=84)Characteristics
Intervention clinical area:
25 (25)20 (24)Cardiovascular
3 (3)4 (5)Endocrinology
10 (10)9 (11)Gastrology and hepatology
21 (21)18 (21)Infectious disease
4 (4)1 (1)Nephrology and urology
2 (2)0 (0)Neurology
4 (4)5 (6)Obstetrics
2 (2)5 (6)Oncology
24 (23)17 (20)Other
6 (6)5 (6)Pulmonology
Population clinical area:
25 (25)25 (30)Cardiovascular
7 (7)4 (5)Endocrinology
9 (9)8 (10)Gastrology and hepatology
15 (14)13 (15)Infectious disease
5 (5)0 (0)Nephrology and urology
1 (1)0 (0)Neurology
7 (7)7 (8)Obstetrics
2 (2)5 (6)Oncology
25 (25)16 (19)Other
5 (5)6 (7)Pulmonology
Journal:
6 (6)8 (10)Annals of Internal Medicine
11 (11)7 (8)BMJ
22 (22)20 (24)Journal of the American Medical Association
19 (19)21 (25)Lancet
42 (41)27 (32)New England Journal of Medicine
1 (1)1 (1)PLoS Medicine
Publication year:
49 (49)40 (48)2005
52 (51)44 (52)2006
Centre status:
9 (9)*19 (23)Single centre
92 (91)*65 (77)Multicentre
Intervention:
61 (60)49 (59)Drugs
7 (7)7 (8)Medical devices
8 (8)4 (5)Surgical procedures
2 (2)7 (8)Health promotion activities
23 (23)17 (20)Other therapeutic technologies
Sponsor:
29 (29)24 (29)Profit
56 (55)49 (59)Not for profit
16 (16)11 (12)Mixed
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;346:f457 doi: 10.1136/bmj.f457 (Published 29 January 2013) Page 8 of 12
RESEARCH
 o
n
 6 July 2020 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.f457 on 29 January 2013. Downloaded from 
Table 1 (continued)
Patient relevant outcomes (n=101)Surrogate outcomes (n=84)Characteristics
741 (300-4731)†371 (162-787)Median (interquartile range) sample size
180 (35-730)255 (133-540)Median (interquartile range) follow-up (days)
*χ2 test, P=0.01.
†Mann-Whitney U test, P<0.001.
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Table 2| Comparison of treatment effects of trials using surrogate outcomes with trials using final patient relevant outcomes: primary and
sensitivity analyses
Ratio of odds ratios or relative risk ratio (95% CI)Risk ratio* (95% CI)
Method of analysis Adjusted†UnadjustedPatient relevant outcomesSurrogate outcomes
Primary analysis:
1.46 (1.05 to 2.04)1.47 (1.07 to 2.01)0.76 (0.70 to 0.82)0.51 (0.42 to 0.60)Binary outcomes (51 surrogate v
83 patient relevant)
Sensitivity analyses:
1.36 (1.08 to 1.70)1.38 (1.12 to 1.71)0.80 (0.75 to 0.86)0.56 (0.48 to 0.65)Inclusion of risk ratios as reported
by authors (57 v 86)
1.48 (0.83 to 2.62)1.44 (0.83 to 2.49)0.68 (0.62 to 0.74)0.46 (0.39 to 0.54)Inclusion of continuous outcomes
(84 v 101)
—1.38 (1.01 to 1.88)0.68 (0.61 to 0.77)0.48 (0.39 to 0.59)Binary outcomes, matched pairs
(43 v 43)
*Pooled using DerSimonian and Laird random effects meta-analyses.
†Adjusted for trial level characteristics of clinical area of intervention, patient population, type of intervention, sponsor, journal, mean sample size, and mean
follow-up time.
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Table 3| Summary of risk of bias assessment for trials reporting biomarkers or intermediate outcomes (surrogate outcomes) versus final
patient relevant primary outcomes
P value*
No (%) of trials
Quality assessment Patient relevant outcomes (n=101)Surrogate outcomes (n=84)
0.1783 (82)62 (74)Intention to treat analysis
0.9965 (64)54 (64)Adequate randomisation sequence generation
0.9274 (73)61 (73)Adequate randomisation allocation concealment
0.3143 (43)42 (50)Double blinding/placebo control
*χ2 test.
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Figures
Fig 1 Flow of studies through inclusion process
Fig 2 Ratio of odds ratios comparing treatment effect estimates in trials using surrogate outcomes versus trials using final
primary end points stratified by key trial characteristics. *P values from tests of interaction between type of primary outcome
and trial characteristics
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;346:f457 doi: 10.1136/bmj.f457 (Published 29 January 2013) Page 12 of 12
RESEARCH
 o
n
 6 July 2020 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.f457 on 29 January 2013. Downloaded from 
